These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24925834)

  • 1. Prostate-specific antigen density toward a better cutoff to identify better candidates for active surveillance.
    Ha YS; Yu J; Salmasi AH; Patel N; Parihar J; Singer EA; Kim JH; Kwon TG; Kim WJ; Kim IY
    Urology; 2014 Aug; 84(2):365-71. PubMed ID: 24925834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is prostate specific antigen (PSA) density necessary in selecting prostate cancer patients for active surveillance and what should be the cutoff in the Asian population?
    Tsang CF; Lai TCT; Lam W; Ho BSH; Ng ATL; Ma WK; Yiu MK; Tsu JHL
    Prostate Int; 2019 Jun; 7(2):73-77. PubMed ID: 31384609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
    Yashi M; Nukui A; Tokura Y; Takei K; Suzuki I; Sakamoto K; Yuki H; Kambara T; Betsunoh H; Abe H; Fukabori Y; Nakazato Y; Kaji Y; Kamai T
    BMC Urol; 2017 Jun; 17(1):47. PubMed ID: 28645325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific Antigen Density Is a Good Predictor of Upstaging and Upgrading, According to the New Grading System: The Keys We Are Seeking May Be Already in Our Pocket.
    Brassetti A; Lombardo R; Emiliozzi P; Cardi A; Antonio V; Antonio I; Aldo S; Tommaso R; Alberto P; Gianluca D
    Urology; 2018 Jan; 111():129-135. PubMed ID: 29032238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
    Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
    BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
    Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
    BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN.
    Sugimoto M; Hirama H; Yamaguchi A; Koga H; Hashine K; Ninomiya I; Shinohara N; Maruyama S; Egawa S; Sasaki H; Kakehi Y;
    World J Urol; 2015 Jul; 33(7):981-7. PubMed ID: 25428792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance.
    Ha YS; Salmasi A; Karellas M; Singer EA; Kim JH; Han M; Partin AW; Kim WJ; Lee DH; Kim IY
    Urology; 2013 Apr; 81(4):831-5. PubMed ID: 23465143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Multi-Parametric Magnetic Resonance Image and PIRADS Score in Patients with Prostate Cancer Eligible for Active Surveillance According PRIAS Criteria.
    Almeida GL; Petralia G; Ferro M; Ribas CA; Detti S; Jereczek-Fossa BA; Matei DV; Coman I; De Cobelli O; Tagliabue E
    Urol Int; 2016; 96(4):459-69. PubMed ID: 27045167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).
    Kato T; Matsumoto R; Yokomizo A; Tohi Y; Fukuhara H; Fujii Y; Mori K; Sato T; Inokuchi J; Hashine K; Sakamoto S; Kinoshita H; Inoue K; Tanikawa T; Utsumi T; Goto T; Hara I; Okuno H; Kakehi Y; Sugimoto M
    BJU Int; 2024 Oct; 134(4):652-658. PubMed ID: 38886979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
    El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
    BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria.
    Russo GI; Cimino S; Castelli T; Favilla V; Urzì D; Veroux M; Madonia M; Morgia G
    Urol Oncol; 2014 Apr; 32(3):291-6. PubMed ID: 24184119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The significance of PSA density as predictive factor in Afro-Caribbean patients eligible for active surveillance by the French protocol criteria].
    Loiselle A; Senechal C; Nevoux P; Benazzouz H; Bhakkan-Mambir B; Casenave J; Gourtaud G; Fofana M; Blanchet P
    Prog Urol; 2014 May; 24(6):327-33. PubMed ID: 24821554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels.
    Kang DI; Jang TL; Jeong J; Choi EY; Johnson K; Lee DH; Kim WJ; Kim IY
    Asian J Androl; 2011 Nov; 13(6):838-41. PubMed ID: 21785442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.